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76 Which cystic ﬁbrosis treatment features matter most to adult
patients and parents of pediatric patients?
A.F. Mohamed1, F.R. Johnson1, M.-M. Balp2, F. Calado1. 1RTI Health Solutions,
Health Preference Assessment, Research Triangle Park, United States; 2Novartis
Pharma AG, HEOR Critical Care, Basel, Switzerland
Objectives: To quantify patient and parent preferences and adherence for different
administration features of inhaled antibiotic medicines for cystic ﬁbrosis (CF).
Methods: Adult patients with a self-reported physician diagnosis of CF and parents
of pediatric CF patients (6 to 17 years) who had Pseudomonas aeruginosa in their
lung culture at least twice in one year completed a web-enabled, discrete-choice
experiment survey in the United States. Respondents answered 5 treatment-choice
questions with known statistical properties. Each question required evaluating a pair
of hypothetical CF treatment proﬁles deﬁned by device type (nebulizer, dry powder
inhaler (DPI), total daily administration and cleaning time, dosing frequency, dry
cough side effect, and personal cost per cycle. Stated adherence questions followed
two randomly selected treatment-choice questions. Random-parameters logit models
were used to estimate preference weights for all feature levels and the mean relative
importance of each feature for both samples.
Results: 209 adult patients and 271 parents completed the survey. Relative impor-
tance estimates indicated that switching from a 30-minute nebulizer twice daily to a
10-minute DPI twice daily was 6.3 times more important for adult patients and 2.0
times more important for parents than an improvement in dry cough from moderate
to mild. Stated adherence for adult and pediatric patients was 20−30% higher for
DPIs versus nebulizers.
Conclusions: Treatments administered with more convenient devices (DPIs) and
shorter administration times are associated with higher utility and higher stated
adherence in adult and pediatric patients.
77 Microbiological monitoring of the respiratory tract in cystic
ﬁbrosis patients
V. Nikonova1, S. Krasovskiy2, E. Kondrateva1, N. Kapranov1. 1Medical Genetics
Researche Center of RAMS, Moscow, Russian Federation; 2Scientiﬁc Research
Institute of Pulmonology FMBA of Russia, Moscow, Russian Federation
Objectives: To conduct microbiological monitoring of the respiratory tract ﬂora in
patients with cystic ﬁbrosis (CF) to assess the effectiveness and optimization of
preventive and therapeutic measures.
Methods: The data of crops 883 CF patients in the Moscow region in 2000–
2008 and 385 patients registration cards in Moscow (770 crops) for the period
in 2010, created with the advice of a European register of CF patients (2008,
European Cystic Fibrosis Society Patient Registry). Inhalation therapy combined
schemes received by 136 patients. 106 patients with chronic pseudomonas infection
have received tobramycin inhalation solution (Toby Bramitob), 30 patients with
ﬁrst isolated Pseudomonas aeruginosa (PA) in sputum have received colistimethate
sodium solution (Colistin). Statistical analysis of the data was performed using
Excel Microsoft Ofﬁce (“Microsoft”), Statistica 7.
Conclusion: The microﬂora structure of the respiratory tract dominated by
Staphylococcus aureus and PA, by the way PA increases from 4 to 25 years.
The number of patients with chronic PA infection in the Moscow region in
2009–2010 decreased by 6% compared with index in 2000–2008 due to ongoing
inhalation antibiotics combined therapy. Infection contamination frequency of PA in
CF patients in Moscow region is 26%, which is comparable with the average data
of European Cystic Fibrosis Society Patient Registry. Using aerosolized antibiotics
(tobramycin) in chronic PA infection leads to the eradication of PA in 30.3%
(Bramitob) and 34.5% (Toby). Using Colistin with ﬁrst isolated PA in sputum
contributes eradication in 87% of patients.
78 Pharmacokinetic variability of clarithromycin and ciproﬂoxacin in
patients with cystic ﬁbrosis (CF)
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Objectives: Clarithromycin (CLA) and especially Ciproﬂoxacin (CIP) are widely used
in the treatment of CF, but not much is known about the pharmacokinetic (PK) in
this group of patients. This is important, since the pharmacodynamics (PD) of CLA is
T>MIC and CIP is AUC/MIC.
We investigated the PK of CLA and CIP in 22 adult CF patients.
Methods: Twenty-two CF patients (21−53 years) with chronic Pseudomonas aerugi-
nosa lung infections were included. 500mg CIP and CLA were given orally and blood
samples were collected every half hour the ﬁrst 3 h and at 6 and 12 h. The concentrations
of CIP were calculated by using a biological assay and CLA and its active metabolite
14-hydroxyCLA were measured by liquid chromatography-tandem mass spectrometry
(LC-MS/MS. AUC, Tmax and Cmax were calculated.
Results: A great individual variation of the PK of CIP and CLA in the 22 CF patients
was observed. For CIP a 14-fold variation, median (range), in AUC (mg/mL x min);
474 (138–1880), and a 30-fold variation in Cmax (mg/mL); 2 (0.25−8) was found. For
CLA a 10-fold variation in AUC (mg/mL x min) median (range) 881 (274–2831) and
a 12-fold variation in AUC (mg/mL x min) for 14-hydroxyCLR median (range) 366
(84–1041) was observed. Variation in Cmax (mg/mL) was 16-fold for CLR median
(range) 3.4 (0.5−8) and 11-fold for 14-hydroxyCLR median (range) 0.9 (0.2−2.2).
Conclusion: The great PK variability may inﬂuence the efﬁcacy of treatment of
CF pathogens, and the development of resistance. Therapeutic drug monitoring or
establishment of the PK is advised to ensure adequate CIP and CLA concentrations
with respect to the PK/PD of these drugs in the individual patient.
79 Microarray analysis of the effect of fosfomycin and tobramycin
against Pseudomonas aeruginosa from CF patients
G. McCaughey1, D.F. Gilpin1, T. Schneiders1, L. Hoffman2, M. McKevitt3,
J.S. Elborn1, M. Tunney1. 1Queen’s University, CF and Airways Microbiology
Research Group, Belfast, United Kingdom; 2University of Washington, School of
Medicine, Seattle, United States; 3Gilead Sciences Inc, Seattle, United States
Background: We have previously demonstrated that a 4:1 (w/w) combination of
fosfomycin/tobramycin (F:T), under investigation for treatment of bacterial respi-
ratory infections, has good activity against CF pathogens, including P. aeruginosa
(PA), with enhanced activity under anaerobic conditions.
Aims: To elucidate the transcriptional basis of increased F:T activity under anaer-
obic conditions.
Methods: A clinical CF PA isolate was grown under aerobic and anaerobic
conditions in sub-inhibitory concentrations of fosfomycin, tobramycin and F:T.
RNA was extracted from log phase culture and mRNA applied to the Affymetrix
PAO1 genome array. Gene expression was compared using ANOVA with p 0.05
indicating signiﬁcant differential expression. Key ﬁndings of array experiments
were conﬁrmed by microbiological assays including susceptibility testing and nitrate
utilisation.
Results: Growth in sub-inhibitory F:T but not tobramycin or fosfomycin alone
signiﬁcantly downregulated (p< 0.05) nitrate reductase genes narG and narH , es-
sential for the anaerobic growth of PA. F:T signiﬁcantly decreased (p< 0.001) nitrate
utilisation in PA isolates PAO1, PA14 and PA14-lasR::Gm, a lasR knockout mutant
known to exhibit increased nitrate utilisation as well as two clinical PA isolates
under anaerobic conditions. Furthermore, nitrate reductase gene knockout mutants
had reduced growth under anaerobic conditions and had increased susceptibility to
F:T compared to wild-type under similar conditions.
Conclusion: Results suggest that downregulation of nitrate reductase genes and
reduced nitrate utilisation is the mechanism underlying the increased activity of
F:T under anaerobic conditions.
